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Abstract
Background: RhoA-Rho kinase complex contributes to keep the cavernosus smooth muscle contracted and its
inhibition is considered a potential strategy for the therapy of erectile dysfunction (ED).
Methods: We compared the effects of SAR407899, the Rho-kinase inhibitor Y-27632 and the PDE5 inhibitor
sildenafil for their ability to relax corpus cavernosum strips contracted with phenylephrine in healthy and diabetic
animals. Strips were obtained from WKY, spontaneous hypertensive (SHR), control CD, and diabetic CD rats,
humans, control and diabetic rabbits. Diabetes was induced by streptozotocin or alloxan injection. In vivo penile
erection (length) induced by drugs was measured in conscious rabbits.
Results: SAR407899 dose-dependently relaxed the pre-contracted corpora cavernosa in all species, with similar potency
and efficacy in healthy vs diabetic rats, WKY vs SHR rats, healthy vs diabetic rabbits (IC50 range from 0.05 to 0.29 μM,
Emax range 89 to 97%). In the presence of the NO-synthase (NOS) inhibitor, L-NAME, the SAR407899 response did not
decrease in any of the species or experimental conditions. The effect was confirmed in human strips where sildenafil
was significantly less potent and effective, with IC50 respectively 0.13 and 0.51 μM; Emax 92 and 43%. Unlike SAR407899,
the potency and efficacy of sildenafil and Y27632 were significantly reduced by diabetes and L-NAME. In vivo,
SAR407899 dose-dependently induced rabbit penile erection, with greater potency and longer duration of action than
sildenafil. Sildenafil, but not SAR407899, was less effective in alloxan-induced diabetes.
Conclusion: The induction of penile erection by SAR407899, unlike that by sildenafil, is largely independent of
e-NO activity. This suggests its use in erectile dysfunction for diabetic and hypertensive patients where e-NO
activity is impaired.
Background
Epidemiological studies indicate that about 50% of men
aged between 40 and 70 years have some degree of erec-
tile dysfunction (ED) which is often related to poor
health or chronic illnesses such as atherosclerosis, dia-
betes mellitus, depression and hypogonadism [1,2]. ED
may also be induced by drugs such as antidepressants,
antihypertensives, viral protease inhibitors and antifun-
gal agents or, less frequently, by physical trauma impair-
ing either the penile arterial supply or spinal cord
function [1,3,4].
Since the arrival of sildenafil in 1998, the type 5 phos-
phodiesterase (PDE5) inhibitors have been the mainstay
for the treatment of virtually any type of ED. Sildenafil
citrate (Viagra
®) was in fact rapidly followed by the intro-
duction, on the worldwide market, of two more PDE5 inhi-
bitors: vardenafil (Levitra
®) and tadalafil (Cialis
®), and
others are in advanced stages of development [5]. This
class of drugs also largely contributed to understanding
the mechanisms involved in penile erection, which results
from a complex interplay of neurotransmitters, neuromo-
dulators, endocrine and intracellular messengers, at both
the central and peripheral levels [6,7].
Erection is basically a spinal reflex that can be
initiated by recruitment of penile afferents but also by
visual, olfactory and imaginary stimuli. Peripherally,
penile erection is a hemodynamic event tuned by
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the smooth muscle cells of the corpus cavernosum and
its arterioles. This is accompanied by increased arterial
blood flow into trabecular spaces which, together with
a block of venous outflow, leads to organ tumescence.
At molecular level, the nitric oxide (NO) transmitter,
locally synthesized by NO-synthase (NOS), rapidly dif-
fuses into the muscle cells and, activating the intracel-
lular enzyme guanylate cyclase, induces the synthesis
of cyclic-guanylyl-monophosphate (cGMP). This sec-
ond messenger eventually leads to smooth muscle
relaxation by triggering a cascade of phosphorylation
reactions and Ca
++-dependent processes [8]. The PDE5
inhibitors promote smooth muscle relaxation and
penile erection by raising the intracellular cGMP con-
centration through selectively inhibiting its enzymatic
degradation by PDE5 [9].
Although essential for penile erection, NO-dependent
cGMP is not the only signaling process responsible for
penile smooth muscle relaxation. Other mechanisms regu-
lating smooth muscle tonus in the penis may be the tar-
gets of new drugs for the treatment of ED [10]. Among
the systems helping keep the cavernous smooth muscles
contracted, the one involving RhoA-Rho-kinase has been
studied most [11]. In the smooth muscle cell RhoA-Rho-
kinase is an important signal transduction pathway com-
posed of the GTP-binding protein, RhoA and its effector
phosphorylating enzyme, Rho-kinase, which is activated by
vasoconstricting agents such as angiotensin, noradrenaline,
endothelin, and platelet-derived growth factor (PDGF)
[12]. When activated, this system keeps the myosin light
chain (MLC) phosphorylated (MLC-P) by inhibiting MLC
phosphatase. This facilitates the interaction between myo-
sin and actin and, by sensitizing Ca
++, eventually promotes
smooth muscle cell contraction (for review see [13]).
T h ee n z y m eR h o - k i n a s ew a sh i g h l ye x p r e s s e di n
human and rabbit cavernosal smooth muscle [14,15]
and it’s in vivo inhibition by a specific antagonist
induced cavernous smooth muscle relaxation and
improved erectile function, particularly in the aging rat
[11,16]. The RhoA/Rho-kinase system is up-regulated in
the cavernosal tissue of aged and spontaneously hyper-
tensive (SHR) rats and rats with experimentally-induced
diabetes [17-19]. Up-regulation of this system might
contribute to the ED associated with aging and the clini-
cal conditions mentioned above.
This view is supported by the improvement of ED
observed in animal models after inhibition of RhoA/
Rho-kinase [20,21]. Therefore inhibition of this enzy-
matic pathway by selective antagonists may prove useful
for the therapy of ED, particularly when associated with
clinical conditions such as metabolic syndrome and type
II diabetes, where current therapies with typical PDE5
antagonists appear to be less satisfactory [22].
One attractive feature of this mechanistic approach is
that the antagonism of RhoA/Rho-kinase stimulates
penile erection through a pathway independent of the
NOS-cGMP pathway [11] and a positive interaction
should be expected between RhoA/Rho-kinase antago-
nists and PDE5 inhibitors. Preclinical studies indicate
that combined treatment with these two types of drugs
is likely to achieve a better erectile response than either
drug separately [19]. RhoA/Rho-kinase antagonists also
have therapeutic potential in hypertension [23].
In the present study we examined the effects of
SAR407899, a novel selective RhoA/Rho-kinase inhibitor,
in vitro on the corpus cavernosum isolated from diabetic,
SHR rats, diabetic rabbits, and humans. L-nitro-arginine-
methyl-ester (L-NAME) was used to investigate the role
of NO in the drug responses in different experimental
conditions. We also assessed in vivo the ability of
SAR407899 to induce penile erection in diabetic rabbits,
compared with the PDE5 inhibitor, sildenafil and the
RhoA/Rho-kinase inhibitor Y-27632, which is widely
used in experimental pharmacology [24].
Methods
Animals
Sexually mature male CD, SHR and WKY (250-600 g) rats
and New Zealand white rabbits (3.5-4.0 kg) were housed
in a room with controlled temperature (22 ± 1°C), humid-
ity (55 ± 10%) and 12-h light-dark cycle for at least ten
days before being used. Food and water were available ad
libitum.
In rats diabetes was induced in our laboratories by a
single intravenous injection (lateral caudate vein) of
streptozotocin (STZ) (50 mg/kg); in rabbits it was
induced in the Charles River Laboratories by a single
intravenous injection of alloxan monohydrate (120 mg/
kg). Body weight and blood glucose levels were assayed
(Accu-Check Go, Roche) each week after the treatments.
The control animals were injected with the vehicle (ster-
ile water). Rabbits with blood glucose concentrations
higher than 300 mg/dL eight weeks after the alloxan
injection, and rats with blood glucose higher than
400 mg/dL three weeks after streptozotocin were con-
sidered diabetic and used for the experiments.
Animals were killed by cervical dislocation, and
penectomy was done immediately. The whole penis was
placed in cold Krebs buffer solution (nM composition:
NaCl 118.4, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, NaHCO3
25, glucose 11.7); the corpus spongiosum, tunica albugi-
nea and the urethra were excised and discarded and
longitudinal strips of corpus cavernosum were isolated
and used for the in vitro preparation.
Animals were euthanized in accordance with the
Sanofi international ethical code and international prin-
ciples governing the care and treatment of laboratory
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Dec.12, 1987) in a fully accredited AAALAC facility.
Human tissues
Human corpus cavernosum tissues for the in vitro experi-
ments were obtained from patients undergoing surgery for
penile prosthesis implantation at San Gerardo Hospital,
Monza, Italy. Patients had not received radiotherapy or
chronic treatment with steroids, opioids or chemotherapy.
Prior to surgery patients had not received PDE5 inhibitors
or other vasoactive agent therapy. Specimens were avail-
able in the operating theater. Fresh tissues were collected
into cold Krebs buffer solution (composition as above)
and used for experiments within 24 hours. This study was
approved by the ethics committee of the San Gerardo
Hospital, Monza, Italy.
In vitro experiments
Each strip was mounted in an organ bath chamber con-
taining 20 ml of Krebs solution maintained at 37°C, con-
stantly aerated with 95% O2 and 5% CO2,a n dl o a d e d
with a resting tension of 1.5 g (rat strips) or 2 g (human
and rabbit strips). Changes in isometric forces were
recorded using a PowerLab data acquisition system
(ADInstruments, Chart 5). After a stabilization period
during which the buffer solution was replaced three
times, the strips were contracted to approximately 80% of
the maximal contraction capacity with phenylephrine:
1 μM (rat), 10 μM (rabbit), 3 μM (human) with or with-
out 0.1 mM L- NAME. When the response to pheny-
lephrine was stable, cumulative concentration-relaxation
response curves of SAR407899, sildenafil, Y27632 or
papaverine at concentrations from 1 nM to 10 μMw e r e
constructed. At the end of the experiments papaverine
(0.1 mM) was added to all preparations as reference stan-
dard for maximal tissue relaxation (100%). A representa-
tive tracing of the relaxant response of SAR 407899 in
rabbit tissues is shown in Figure 1. Results were
expressed as the concentration reducing the phenylephr-
ine-induced contractions by 50% (IC50). The %Emax was
the maximal response obtained with the compound cal-
culated as a percentage of papaverine-induced maximal
relaxation.
Emax and IC50, were calculated using a four-parameter
logistic model according to Ratkovsky & Reedy, with
adjustment by non-linear regression, using Biost@t Speed
V2.0 LTS internal software. If necessary, asymptotes were
constrained. The adjustment was obtained by non-linear
regression using the Marquardt algorithm in SAS
® v9.1
software under UNIX. Values are given with their confi-
dence intervals. For the rat isolated corpus cavernosum
one-way analysis of variance (ANOVA) followed by New-
man-Keuls test. For the rabbit isolated corpus cavernosum
three-way ANOVA on log-transformed IC50 and rank-
transformed %Emax was done, followed by Winer test.
Analyses were carried out using SAS
® v8.2 for Sun Solaris
via Everstat v5.0 interface. Three-way ANOVA was done
Variance using SAS
® v9.1.
In vivo experiments
Rabbits were treated either intravenously (i.v., in an ear
vein) with increasing doses of SAR407899 (0.3, 1, 3, 10
mg/kg) or orally with SAR407899 (1, 3, 10, 30 mg/kg)
or sildenafil (2 or 6 mg/kg). Each animal was used sev-
eral times for different doses and different agents, always
with a week’s washout. The length (mm) of uncovered
penile mucosa (penile erection parameter) was measured
at different time-points, using a sliding digital caliper.
The results were expressed as mean ± SEM penile
length of 3-5 rabbits.
T h ea r e au n d e rt h ec u r v e( A U C )w a sc a l c u l a t e df o r
each animal in each group, and was expressed as mean
± SEM. For descriptive statistics, one-way ANOVA was
done, followed by Newman-Keuls test versus the 6 mg/
kg sildenafil group, using SAS
® v8.2 for Sun Solaris via
Everstat v5.0 interface.
Drugs
L-phenylephrine hydrochloride (Sigma Batch 7 1 K1725,
stock solution 1 mM), L-NAME (Sigma Batch L0051,
stock solution 100 mM), SAR407899 (batch F37096-038,
stock solution 1 mM) and Y27632 (batch 066 K47001,
stock solution 1 mM) were prepared in bi-distilled water.
Papaverine HCl (Sigma Batch 107H1206, stock solution
10 mM) was dissolved in 2% ascorbic acid w/v in bi-dis-
tilled water. Sildenafil was either extracted from commer-
cial 50 mg Viagra
® tablets, as described by Zoma [25] (the
concentration of the solution was determined and analysis
was done by Sanofi Discovery Analytics), or synthesized
by Sanofi (SL412290, stock solution 1 mM in citric acid/
DMSO/bi-distilled water 0.4/4/95.6 v/v/v). Unless other-
wise specified all substances were diluted in bi-distilled
water as necessary.
Results
In vitro functional activity in control-healthy and
diabetic CD rats
In the in vitro preparation of rat corpus cavernosum,
SAR407899 dose-dependently relaxed the phenylephrine
pre-contracted smooth muscle to 98% of maximal relaxa-
tion, equivalent to the efficacy of papaverine (Table 1). Its
potency was similar in control and diabetic animals, IC50
μM 0.07 and 0.05, respectively and was not significantly
different from the IC50 o ft h et y p e5p h o s p h o d i e s t e r a s e
inhibitor sildenafil, or the RhoA/Rho-kinase inhibitor
Y27632. In rats with streptozotocin diabetes SAR407899
retained the same potency and efficacy as in preparations
from healthy rats. Unlike SAR407899, sildenafil and
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betic than controls rats, IC50 0.17 μM vs 0.04 μM and 0.16
μM vs 0.05 μM respectively. The maximal relaxation with
sildenafil was also lower in diabetic (83%) than non-dia-
betic (95%) rats.
In vitro functional activity in SHR rats and in the same
wild-type normotensive strain (WKY)
Table 2 reports the in vitro effects of SAR407899, silde-
nafil and Y27632 on phenylephrine-precontracted
corpus cavernosum from SHR rats and rats from the
same wild-type normotensive strain (WKY), with and
without the NO-synthase inhibitor L-NAME. In WKY
rats all three drugs had similar potency, IC50 0.10, 0.09,
0.02 μM respectively. In SHR rats, the rank order of
potency of the three compounds was similar but with
slightly higher IC50 (0.29, 0.19, 0.08 μM respectively). In
presence of L-NAME sildenafil and Y 27632 were less
potent both in normotensive (IC50 0.18, 0.61 μMv s
0.02, 0.09 μM respectively) and hypertensive rats (IC50
PHE 
10μM 
SAR407899A
1nM=>10μM 
PAPAVERINE
0.1mM 
L-NAME 
0.1mM 
PHE 
10μM 
SAR407899A
1nM=>10μM 
PAPAVERINE
0.1mM 
Figure 1 Representative isometric recorded tracing of SAR407899 effect in isolated corpus cavernosum strips dissected from diabetic
rabbits.
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Page 4 of 110.34, 0.56 μM vs 0.08, 0.19 μM respectively) but with a
larger difference in the former (9- and 7-fold) than in
the latter (4- and 3-fold). By contrast SAR407899
response was almost unaffected by L-NAME in any
experimental condition.
In vitro functional activity in control-healthy and diabetic
rabbits
The superior and qualitatively different activity of
SAR407899 as smooth muscle relaxant compared to sil-
denafil was confirmed using the in vitro preparation of
corpus cavernosum from healthy rabbits and rabbits
with alloxan-induced diabetes. This test was done with
and without L-NAME (Table 3). In the absence of L-
NAME, SAR407899 relaxed the corpus cavernosum of
normal rabbits with similar potency and efficacy to sil-
denafil (IC50 0.40, 0.22 μM and Emax 95, 83% respec-
tively). With L-NAME, SAR407899 had similar potency
and efficacy in control and diabetic rabbits (IC50 0.28,
0.42 μM respectively), and its response was not affected
whereas, in contrast, the potency, and particularly the
efficacy, of sildenafil was drastically lower in prepara-
tions from diabetic rabbits and in the presence of L-
NAME (IC50 1.13, 1.45 μM respectively).
In vivo activity on penile erection in healthy-control and
diabetic rabbits
The effects of SAR407899 on penile erection in vivo in
rabbits are shown in Figures 2, 3 and 4. Intravenous
SAR407899 dose-dependently increased the length of
the penis, starting from 1 mg/kg and with a maximal
effect already at 3 mg/kg (Figure 2). Oral SAR407899 (3
and 10 mg/kg) also increased penile length and its effect
was significantly more potent and longer lasting than
sildenafil 6 mg/kg (AUC 2880 ± 314 vs. 680 ± 278). At
the supra-maximal dose of 30 mg/kg, SAR407899 had
still a near-maximal effect after 6 hours (Figure 3). In
diabetic rabbits, oral SAR407899 (3-10 mg/kg) also
dose-dependently increased penile length whereas oral
Sildenafil (6 mg/kg) caused a similar increase of penile
length but with less marked effects (Figure 4).
Table 1 In vitro relaxation of phenylephrine-pre-
contracted strips from control or diabetic rats by
SAR407899, Y 27632 and sildenafil
RELAXATION OF RAT CORPUS CAVERNOSUM
IC50, μM (95% confidence interval)
%Emax ± SEM
Controls Diabetes
SAR407899 0.07 0.05
(0.03-0.17) (0.03-0.10)
98 ± 2.1 97 ± 3.1
Y27632 0.05 0.16 °°
(0.02-0.09) (0.07-0.36)
93 ± 1.6 98 ± 1.5
SILDENAFIL 0.04 0.17 °°
(0.001-0.23) (0.003-0.83)
95 ± 4.0 83 ± 4.3
Maximal effect is expressed as a percentage of the relaxation induced by 0.1
mM papaverine. Results were analyzed by one-way ANOVA + Newman-Keuls
test. Significance of differences between groups: ○○p < 0.001 vs. CD control
Table 2 In vitrorelaxation of phenylephrine-pre-
contracted strips from normotensive WKY or genetically
hypertensive (SHR) rats by SAR407899, sildenafil and Y
27632: effect of the NO synthase inhibitor L-NAME (0.3
mM)
RELAXATION OF RAT CORPUS CAVERNOSUM
IC50, μM (95% confidence interval)
%Emax ± SEM
WKY SHR
— L-NAME — L-NAME
SAR407899 0.10
(0.009-
1.270)
89 ± 3.5
0.13
(0.021-
0.901)
86 ± 2.4
0.29
(0.189-
0.460)
94 ± 1.3
0.28
(0.213-
0.384)
94 ± 1.2
SILDENAFIL 0.02 0.18 ** 0.08 0.34 **
(0.014-0.060) (0.048-0.716) (0.039-0.155) (0.146-0.814)
91 ± 3.4 77 ± 5.7 82 ± 3.0 65 ± 3.6
Y 27632 0.09 0.61 0.19 0.56
(0.030-0.299) (0.373-1.025) (0.031-1.147) (0.272-1.185)
92 ± 3.2 89 ± 3.7 92 ± 2.5 87 ± 2.3
Maximal effect is expressed as a percentage of the relaxation induced by 0.1
mM papaverine. Results were analyzed by one-way ANOVA + Newman-Keuls
test. Significance of differences between groups: ** p < 0.003 vs. without
L-NAME
Table 3 In vitro relaxation of phenylephrine-pre-
contracted corpora cavernosa from normal (control) or
diabetic rabbits by SAR407899 and sildenafil: effect of
the NO synthase inhibitor L-NAME (0.3 mM)
RELAXATION OF RABBIT CORPUS CAVERNOSUM
IC50, μM (95% confidence interval)
%Emax ± SEM
Controls Diabetes
— L-NAME — L-NAME
SAR407899 0.40 0.28 ** 0.42 ## 0.42
○○
(0.23-0.69) (0.13-0.60) (0.20-0.90) (0.14-1.26)
95 ± 1.4§ 93 ± 2.3*** 95 ± 1.4### 96 ± 1.4
○○○
SILDENAFIL 0.22 1.13 1.45 1.47
(0.11-0.45) (0.35-3.66) (0.27-7.81) (1.01-2.14)
83 ± 2.3 65 ± 9.9 65 ± 9.6 45 ± 5.3
Maximal effect is expressed as a percentage of the relaxation induced by 0.1
mM papaverine. Results were analyzed by three-way ANOVA + Winer analysis.
Significance of differences between groups: § p < 0.05 vs. sildenafil control
(-L-NAME); ** 0.001 < p < 0.01 vs. sildenafil control (+L-NAME); ***p < 0.001
vs. sildenafil control (+L-NAME); ## 0.001 < p < 0.01 vs. sildenafil control (-L-
NAME); ### p < 0.001 vs. sildenafil control (-L-NAME); ○○ 0.001 < p < 0.01 vs.
sildenafil diabetic (+L-NAME); ○○○p < 0.001 vs. sildenafil diabetic (+L-NAME)
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cavernosum
The activity of SAR407899 was confirmed on prepara-
tions of human corpus cavernosum in vitro pre-con-
tracted with 3 μM phenylephrine (Figure 5).
SAR407899 fully relaxed the corpus cavernosum smooth
muscle with the same potency and efficacy with or without
L-NAME (IC50 0.18 and 0.13 μM and max. relaxation vs.
papaverine 94 and 92%). Without L-NAME sildenafil was
significantly less potent and effective (IC50 0.51 μM, max.
relaxation vs. papaverine 43%) than SAR407899. The
potency, and particularly the efficacy of sildenafil was even
lower in preparations with L-NAME (IC50 0.78 μM, max.
relaxation vs. papaverine 26%).
Discussion
SAR407899 is a highly selective Rho-kinase inhibitor
that relaxes pre-contracted isolated arteries from differ-
ent animal species and lowers blood pressure in rodent
models of arterial hypertension [23].
I nt h i ss t u d yw ee x a m i n e dt h ein vitro and in vivo
actions of SAR407899 on penile tissue function in order
to assess its potential value for the treatment of ED.
This investigation might further contribute to under-
standing the importance of the Rho/Rho-kinase bio-
chemical pathway for penile erection, particularly in
diabetic patients.
SAR407899A was a potent in vitro relaxant of pheny-
lephrine pre-contracted corpora cavernosa smooth
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Figure 2 Dose-dependent effect of intravenous SAR407899 on penile erection in normal rabbits. Each point represents the average of
three animals. Penile length in mm is plotted against the time of drug injection in minutes (AUC).
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Page 6 of 11muscles from rat, rabbit and man. In addition to this in
vitro action the drug also promoted penile erection in
vivo in rabbits with experimentally-induced diabetes, a
pathology frequently associated with ED in man
[2,17,22].
In vitro, we added phenylephrine to the bath to mimic
the in vivo situation in which cavernosal smooth muscle
contraction is maintained by a-receptor stimulation by
noradrenaline released from adrenergic nerves, leading
to a flaccid state of the penis. SAR407899 was fully
effective and had approximately the same potency in
relaxing pre-contracted cavernosal smooth muscles from
control and streptozotocin diabetic or spontaneous SHR
rats. The PDE5 inhibitor sildenafil relaxed the contracted
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Figure 3 Penile erection in normal rabbits after oral SAR407899 or sildenafil. Each point represents the average of three-five animals Penile
length in mm is plotted against the time of drug injection in minutes (AUC) 0.001 < p < 0.01 vs. sildenafil 6 mg/kg (one-way ANOVA +
Newman-Keuls), *** p < 0.001 vs. sildenafil 6 mg/kg (one-way ANOVA + Newman-Keuls).
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Page 7 of 11preparations less than SAR407899 and was at least four
times less potent in relaxing preparations from diabetic
and SHR rats, compared to normal rats. The difference
between the potency of SAR407899 and sildenafil in
relaxing preparations from diabetic and healthy animals
was confirmed, and even magnified, in rabbit corpora
cavernosa. In these experiments, SAR407899 showed the
same potency and efficacy in preparations from healthy
and alloxan diabetic rabbits while sildenafil was much
less potent and effective in diabetic rabbits.
It is important to recall that Rho-kinase is highly
expressed in cavernosal smooth muscle cells of man
and other mammals [14] and is up-regulated in
corpora cavernosa of aging and diabetic animals, and
animals with spontaneous hypertension [17-19]. The
hyperfunction of this signaling pathway, which sup-
presses endothelial nitric oxide synthase (e-NOS), may
be one mechanism leading to ED associated with aging,
diabetes and cardiovascular hypertension [17,18,22,26].
Consequently, inhibition of this pathway by a selective
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Figure 4 Penile erection in diabetic rabbits after oral SAR407899 in comparison with sildenafil. Each point represents the average of
three-six animals Penile length in mm is plotted against the time of drug injection in minutes (AUC). ** 0.001 < p < 0.01 vs. sildenafil 6 mg/kg
(one-way ANOVA + Newman-Keuls), §§ 0.001 < p < 0.01 vs. SAR407899A 10 mg/kg (one-way ANOVA + Newman-Keuls).
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and diabetic rodents [16,20,21].
In our study Y-27632, used as reference compound for
the activity of SAR407899 on rat corpus cavernosum,
relaxed this preparation with potency and efficacy simi-
lar to that of SAR407899. Unlike SAR407899, however,
it was slightly less potent in relaxing corpora cavernosa
from streptozotocin diabetic rats than from normal rats.
It is hard to explain this difference between two com-
pounds believed to act with a common mechanism of
action. Since basal release of NO from the endothelium
seems to be present in organ chamber setting as
reflected by sildenafil and L-NAME effects, the impact
of NOS inhibition on Y27632 could be explained by the
loss of its effects through Rho-kinase inhibition-
mediated NOS activation. Alternatively the superior
selectivity of SAR407899 over Y-27632 as Rho-kinase
inhibitor might at least partially explain it [23].
It has been reported that Rho-kinase antagonism sti-
mulates penile erection in rats by a mechanism that is
not primarily dependent on the NO pathway which,
instead, is required for the activity of PDE5 inhibitors
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Page 9 of 11[11,19]. Therefore, to confirm the specificity of
SAR407899 as Rho-kinase antagonist in the animal
models of ED, we tested its ability to relax corpora
cavernosa of normotensive and hypertensive rats and
of normal and diabetic rabbits in the presence of the
NO-synthetase inhibitor, L-NAME. As expected,
SAR407899 was equally effective as a relaxing agent
with and without L-NAME in all experimental condi-
tions, while sildenafil was from four to eight times less
active in the presence of L-NAME in preparations
from normotensive and hypertensive rats, and in those
from healthy and diabetic rabbits. It is noteworthy that
sildenafil had similarly lower potency in diabetic than
healthy rabbit preparations with L-NAME. This sug-
gests that sildenafil is largely dependent on NOS activ-
ity in corpus cavernosum relaxation. We confirmed
that SAR407899, unlike sildenafil, also acts through the
same mechanism on human tissue, where its potency
and efficacy in vitro on phenylephrine-precontracted
corpora cavernosa with and without L-NAME were
similar.
All these results point to different molecular mechan-
isms for ED in healthy and diabetic animals and suggest
that SAR407899, by selectively acting on the RhoA/Rho-
kinase pathway, might be more effective than sildenafil
and other PDE5 inhibitors in improving ED in diabetic
patients. This conclusion is further supported by the in
vivo results with SAR407899 in normal and alloxan-
induced diabetic rabbits. The superior potency of
SAR407899 over sildenafil was evident when the com-
pound was given orally to non-diabetic rabbits. Peak
effects in inducing penile erection were similar after 3
mg/kg SAR407899 and 6 mg/kg sildenafil, but the effect
of the former began later and lasted much longer, con-
firming its oral bioavailability and long-lasting action
already reported in other species [23]. Most important,
SAR407899, unlike sildenafil, retained at least the same
potency and efficacy in diabetic rabbits. This was clear
from the similar or even larger AUC in the plot of
penile length against time at the oral dose of 10 mg/kg
SAR407899.
Conclusion
This study showed that the highly selective Rho-kinase
inhibitor SAR407899 is a relative potent relaxing agent
of corpora cavernosa from different animal species and
man. These results, in stimulation of penile erection,
may be useful in the prevention and therapy of a num-
ber of erectile dysfunctions, particularly those depending
on hyper-functioning of the RhoA/Rho-kinase system,
such as diabetes and hypertension. Future studies are
required to confirm the potential of this compound and
other more powerful molecules for ED.
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